Tecentriq 840mg injection is an anticancer medication containing the active ingredient Atezolizumab which belongs to the class of medicine called monoclonal antibodies (Mab). It is indicated to treat cancer in the bladder, lungs, liver, and breast. Mab is a type of protein that gets attached to a specific target in the body. This antibody helps the immune system to fight against cancer. This medicine is used as adjuvant therapy (treatment after surgery) for lung cancer conditions where the cancer is not spread to other body parts. It is either used alone or in a combination with other anticancer medicine. 

Do not take a Tecentriq 840mg injection if you are allergic to Atezolizumab or other medicine ingredients. This medicine is not recommended for children and adolescents. Notify your healthcare professional if you experience any symptoms like inflammation of the lung, liver, intestine, thyroid, adrenal glands, and pituitary gland; your doctor might prescribe other medications to prevent complications and reduce the symptoms. 

Before taking Tecentriq 840mg, inform your doctor if you have or ever had an autoimmune disease (the body attacks its cells), HIV infection or AIDS, a past with pneumonitis (inflammation of the lung), infections like HIV/AIDS, or a chronic viral infection of the liver (hepatitis B / hepatitis C). Also, notify me if you have been given any live, attenuated vaccine; antibiotic within the two weeks; or any medicine to improve or suppress your immune system. Report your doctor if you are pregnant or planning to get pregnant. Use effective birth control during and even after the treatment for five months.

• Urothelial carcinoma
• Non-small cell lung cancer
• Small cell lung cancer
• Triple-negative breast cancer
• Hepatocellular carcinoma

Tecentriq 840mg is a monoclonal antibody that blocks the interaction between PD-L1 and PD-1, which can help the T-cells recognize and attack cancer cells more effectively. By doing so, Tecentriq 840mg can stimulate the immune system to attack cancer cells and potentially slow down or stop cancer growth.

A trained doctor or nurse should only administer it. Do not self-administer the injection. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for unwanted side effects. The first infusion will take around 60 minutes and must be monitored carefully. If there is no infusion reaction for the first dose, the next infusion will last 30 minutes.

Serious:

Inflammation (lung, liver, intestine, thyroid, adrenal glands, and pituitary gland)

Type 1 diabetes

Inflammation of the brain, heart muscle, kidney, muscle

Severe skin reaction

Inflammation of problem with nerve

Common:

Fever

Loss of appetite

Urinary tract infection

Pain in the joints, muscles, and bones

Headache

Hair loss

Numbness in hands and feet

Sensitivity to sun

Constipation

Low oxygen level

High blood sugar

Pain in stomach, mouth, and throat

Inform your healthcare provider about all the medicines you take, including prescription, over-the-counter, nutritional supplements, and herbal products. In particular, tell your doctor if you are taking medicines for blood pressure or other heart conditions. Certain medications may interact with Tecentriq 840mg and reduce its effectiveness by causing undesirable side effects.

• Store Tecentriq 840mg in the refrigerator (2°C to 8°C)
• Do not freeze.
• Keep the injection away from the reach of children and pets.
• If you have missed any dosing appointments, inform your doctor and schedule immediately.

Notify our doctor if you are taking or have recently taken any other medications. Before starting the treatment, it is advised to have a blood test and general health check-up. Report to your doctor if you experience any side effects; your doctor may delay. This medicine is not recommended for children and adolescents under 18 years. Before starting the treatment, inform your doctor if your cancer cell has spread to the brain.